Results 11 to 20 of about 141,477 (341)

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation [PDF]

New England Journal of Medicine, 2001
BACKGROUND Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in
Salim Yusuf, Fei-Li Zhao, Shaesta Mehta, Susan Chrolavicius, Gianni Tognoni, Kimberley Fox, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators   +6 more
semanticscholar   +7 more sources

The Role of Clopidogrel in 2020: A Reappraisal

Cardiovascular Therapeutics, 2020
Antiplatelet therapy is the mainstay of treatment and secondary prevention of cardiovascular disease (CVD), including acute coronary syndrome (ACS), transient ischemic attack (TIA) or minor stroke, and peripheral artery disease (PAD).
Giuseppe Patti, Giuseppe Micieli, Claudio Cimminiello, Leonardo Bolognese   +3 more
doaj   +2 more sources

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

Clinical pharmacology and therapy, 2022
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition ...
Craig R. Lee, Jasmine A. Luzum, K. Sangkuhl, Roseann S. Gammal, M. Sabatine, C. Stein, D. Kisor, N. Limdi, Yee Ming Lee, S. Scott, J. Hulot, D. Roden, A. Gaedigk, K. Caudle, T. Klein, Julie A. Johnson, A. Shuldiner   +16 more
semanticscholar   +1 more source

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.

JAMA cardiology, 2022
Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS).
Hirotoshi Watanabe, T. Morimoto, M. Natsuaki, Ko Yamamoto, Y. Obayashi, M. Ogita, S. Suwa, T. Isawa, T. Domei, K. Yamaji, Shojiro Tatsushima, Hiroki Watanabe, M. Ohya, H. Tokuyama, T. Tada, H. Sakamoto, Hiroyoshi Mori, Hiroshi Suzuki, Tenjin Nishikura, K. Wakabayashi, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, Y. Morino, K. Kadota, Y. Furukawa, Y. Nakagawa, T. Kimura   +31 more
semanticscholar   +1 more source

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.

New England Journal of Medicine, 2021
BACKGROUND Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Yongjun Wang, Xia Meng, Anxin Wang, Xuewei Xie, Yuesong Pan, S. Johnston, Hao Li, P. Bath, Q. Dong, Anding Xu, J. Jing, Jinxi Lin, Siying Niu, Yilong Wang, Xingquan Zhao, Zixiao Li, Yong Jiang, Wei Li, Liping Liu, Jie Xu, L. Chang, Lihua Wang, Xianbo Zhuang, Jinguo Zhao, Yefang Feng, Honghao Man, Guozhong Li, Baojun Wang   +27 more
semanticscholar   +1 more source

Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study

Circulation, 2022
Background: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Extended Antiplatelet Monotherapy ...
Jeehoon Kang, Kyung-Woo Park, H. Lee, D. Hwang, Han-Mo Yang, S. Rha, J. Bae, N. Lee, S. Hur, J. Han, E. Shin, B. Koo, Hyo‐Soo Kim   +12 more
semanticscholar   +1 more source

Clopidogrel (Plavix) [PDF]

American Journal of Neuroradiology, 2011
Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with ...
J, Comin, D, Kallmes
openaire   +2 more sources

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2020
Importance After percutaneous coronary intervention (PCI), patients with CYP2C19*2 or *3 loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic events.
N. Pereira, M. Farkouh, D. So, R. Lennon, N. Geller, V. Mathew, M. Bell, J. Bae, M. Jeong, Ivan J. Chavez, Paul Gordon, J. Abbott, C. Cagin, L. Baudhuin, Yi-Ping Fu, S. Goodman, S. Goodman, Ahmed A Hasan, E. Iturriaga, A. Lerman, M. Sidhu, J. Tanguay, Liewei Wang, R. Weinshilboum, R. Welsh, Y. Rosenberg, K. Bailey, C. Rihal   +27 more
semanticscholar   +1 more source

Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

Journal of Pharmaceutical Health Care and Sciences, 2020
Background Repaglinide is widely prescribed to reduce postprandial hyperglycemia and elevated glycated hemoglobin (HbA1c) levels associated with type 2 diabetes, and clopidogrel is a thienopyridine antiplatelet agent and widely used in cardiovascular and
Yuuki Akagi, Akiko Iketaki, Haruna Kimura, Yuki Matsudaira, Takami Yoshida, Takahiro Nishimura, Yohei Kawano, Yasunari Mano, Erina Shigematsu, Makoto Ujihara   +9 more
doaj   +1 more source

The Use of Prasugrel and Ticagrelor in Pipeline Flow Diversion [PDF]

, 2018
Background: Despite the routine clopidogrel/aspirin anti-platelet therapy, complications like thromboembolism, continue to be encountered with PED.
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Eller, MD, Gorge, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA MD, Robert H., Saad, MD, Hassan, Stidd, MD, David, Tjoumakaris, MD, Stavropoula   +9 more
core   +2 more sources